Roberta Siegwart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberta Siegwart has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Rachel Jurd
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
1 shared publicationUwe Rudolph
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
1 shared publication
Latest Publications
- 28 December 2001
- Published by Wiley in Journal of Neurochemistry
- Vol. 80 (1) , 140-148
Molecular determinants for the action of general anesthetics at recombinant α2β3γ2γ‐aminobutyric acidA receptors
General anesthetics modulate the activity of ligand‐gated ion channels including the GABAA receptor. Mutational studies mainly on the benzodiazepine‐insensitive α2β1(M286W) and α6β3(N289M)γ2 GABAA receptors revealed that a serine in transmembrane domain 2 and a methionine in transmembrane domain 3 are essential for the action of most general anesthetics. We investigated whether these residues would similarly be relevant for their action at the benzodiazepine‐sensitive GABA receptor subtype, α2β3γ2. We found that not only the N265M but also the M286W mutation nearly abolished the modulatory effect of etomidate. However, the anti‐convulsant loreclezole, a structural homologue of etomidate, was inactive on the N265M mutant, but displayed normal modulatory activity on the M286W mutant. Both mutations did not affect the modulatory action of the neurosteroid alphaxalone. The direct action of alphaxalone, however, was dramatically increased in the M286W mutant to about twice the maximal GABA current but not significantly affected in the N265M mutant. These data demonstrate that the structural requirements for modulatory and direct actions of various general anesthetics are distinct. The molecular switches induced by these mutations can be exploited to identify the molecular determinants for the action of general anesthetics.
- 28 December 2001
- Published by Wiley in Journal of Neurochemistry
- Vol. 80 (1) , 140-148
Molecular determinants for the action of general anesthetics at recombinant α2β3γ2γ‐aminobutyric acidA receptors
General anesthetics modulate the activity of ligand‐gated ion channels including the GABAA receptor. Mutational studies mainly on the benzodiazepine‐insensitive α2β1(M286W) and α6β3(N289M)γ2 GABAA receptors revealed that a serine in transmembrane domain 2 and a methionine in transmembrane domain 3 are essential for the action of most general anesthetics. We investigated whether these residues would similarly be relevant for their action at the benzodiazepine‐sensitive GABA receptor subtype, α2β3γ2. We found that not only the N265M but also the M286W mutation nearly abolished the modulatory effect of etomidate. However, the anti‐convulsant loreclezole, a structural homologue of etomidate, was inactive on the N265M mutant, but displayed normal modulatory activity on the M286W mutant. Both mutations did not affect the modulatory action of the neurosteroid alphaxalone. The direct action of alphaxalone, however, was dramatically increased in the M286W mutant to about twice the maximal GABA current but not significantly affected in the N265M mutant. These data demonstrate that the structural requirements for modulatory and direct actions of various general anesthetics are distinct. The molecular switches induced by these mutations can be exploited to identify the molecular determinants for the action of general anesthetics.